# Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests

- Source: Seeking Alpha Market Currents
- Published: 2026-11-06T04:55:31+00:00
- Category: Markets
- Original: https://seekingalpha.com/news/4667760-veracyte-outlines-2027-view-with-10-percent-volume-growth-and-22-percent-adjusted-ebitda?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
- Canonical: https://groundlevelnews.com/story/veracyte-outlines-2027-view-with-10-volume-growth-and-22-adjusted-ebit-afc6fb/

Read the full report from the original publisher.

_Ground Level News shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents._